Trichloroethylene

CASRN 79-01-6

IRIS Summary (PDF) (63 pp, 520 K)
Supporting Documents for Trichloroethylene
Status: Trichloroethylene is not being reassessed by IRIS at this time.

Key IRIS Values
Organ/System Specific Values
History

Health Hazard Assessments for Effects Other than Cancer

Reference Dose for Oral Exposure (RfD) (PDF) (63 pp, 520 K) last updated: 09/28/2011

RfD (mg/kg-day)	System	Basis	POD	Composite UF	Confidence
5x10^-4 (Chronic)*	Multiple*	Multiple*	Multiple*	Multiple*	Multiple*

* System-specific RfDs information used to establish RfD

Reference Concentration for Inhalation Exposure (RfC) (PDF) (63 pp, 520 K) last updated: 09/28/2011

RfC (mg/m³)	System	Basis	POD	Composite UF	Confidence
0.002 (Chronic)*	Multiple*	Multiple*	Multiple*	Multiple*	Multiple*

* System-specific RfCs information used to establish RfC

Cancer Assessment

Weight of Evidence for Cancer (PDF) (63 pp, 520 K) last updated: 09/28/2011

WOE Characterization	Framework for WOE Characterization
Carcinogenic to humans	Guidelines for Carcinogen Risk Assessment (US EPA, 2005)

Basis:

Following U.S. EPA (2005b) Guidelines for Carcinogen Risk Assessment, TCE is characterized as "carcinogenic to humans" by all routes of exposure.
This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (63 pp, 520 K)

Oral Slope Factor: 4.6 x10^-2 per mg/kg-day
Extrapolation Method: PBPK model-based route-to-route extrapolation of the inhalation unit risk estimate for kidney cancer with a factor of 5 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk
Tumor site(s): Hematologic, Hepatic, Urinary
Tumor type(s): Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors (Charbotel et al., 2006 EPA, 2011 Raaschou-Nielsen et al., 2003)

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (63 pp, 520 K)

Inhalation Unit Risk: 4.1 x10^-6 per µg/m³
Extrapolation Method: Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk
Tumor site(s): Hematologic, Hepatic, Urinary
Tumor type(s): Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors (Charbotel et al. 2006 EPA, 2011 Raaschou-Nielsen et al., 2003)

Organ/System-Specific RfDs:

System	Basis	RfD (mg/kg-day)	POD	UF	Confidence
Developmental, Cardiovascular	Increased fetal cardiac malformations in Sprague-Dawley rats	5.1 x 10^-4	BMDL₀₁ (HED₉₉): 0.0051 mg/kg-day	10	Medium
Immunological	Decreased thymus weight in female B6C3F1 mice	4.8 x 10^-4	LOAEL (HED₉₉): 0.048 mg/kg-day	100	Medium/High
Immunological, Developmental	Decreased plaque-forming cell (PFC) response, increased delayed-type hypersensitivity in B6C3F1 mice	3.7 x 10^-4	LOAEL: 0.37 mg/kg-day	1000	Medium/High

Organ/System-Specific RfCs:

System	Basis	RfC (mg/m³)	POD	Composite UF	Confidence
Developmental, Cardiovascular	Increased fetal cardiac malformations in Sprague-Dawley rats	0.0021	BMDL01 (HEC₉₉): 0.021 mg/m³	10	Medium
Immunological	Decreased thymus weight in female B6C3F1 mice	0.0019	LOAEL (HEC₉₉): 0.19 mg/m³	100	Medium/High